| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $10,032,497 | 21 | 100 |
| Taylor Ben R | Chief Financial Officer | 0 | $0 | 1 | $89,381 | $-89,381 |
| Khan Najat | Chief R&D Commercial Officer | 0 | $0 | 2 | $750,765 | $-750,765 |
| Borgeson Blake | director | 0 | $0 | 2 | $1.92M | $-1.92M |
| Gibson Christopher | Chief Executive Officer | 0 | $0 | 16 | $7.27M | $-7.27M |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Over the last 12 months, insiders at Recursion Pharmaceuticals, Inc. have bought $0 and sold $10.03M worth of Recursion Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Recursion Pharmaceuticals, Inc. have bought $44.16M and sold $14.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 66,822 shares for transaction amount of $522,354 was made by Mubadala Investment Co PJSC (10 percent owner) on 2023‑03‑02.
| 2026-01-20 | Sale | Gibson Christopher | director | 40,000 0.0101% | $4.47 | $178,800 | +9.28% | |
| 2026-01-06 | Sale | Borgeson Blake | director | 220,000 0.0548% | $4.36 | $959,200 | +5.28% | |
| 2026-01-05 | Sale | Gibson Christopher | director | 40,000 0.0097% | $4.25 | $170,000 | +9.69% | |
| 2025-12-29 | Sale | Taylor Ben R | Chief Financial Officer | 21,383 0.0052% | $4.18 | $89,381 | +13.37% | |
| 2025-12-22 | Sale | Khan Najat | Chief R&D Commercial Officer | 124,403 0.0312% | $4.41 | $548,592 | +2.03% | |
| 2025-12-19 | Sale | Gibson Christopher | Chief Executive Officer | 40,000 0.0105% | $4.50 | $180,000 | +2.85% | |
| 2025-12-04 | Sale | Gibson Christopher | Chief Executive Officer | 40,000 0.0094% | $4.63 | $185,200 | -1.20% | |
| 2025-12-02 | Sale | Borgeson Blake | director | 220,000 0.0555% | $4.37 | $961,400 | +3.98% | |
| 2025-11-19 | Sale | Gibson Christopher | Chief Executive Officer | 40,000 0.0103% | $4.16 | $166,400 | +11.54% | |
| 2025-11-04 | Sale | Gibson Christopher | Chief Executive Officer | 40,000 0.0088% | $5.21 | $208,400 | -9.95% | |
| 2025-10-10 | Sale | Gibson Christopher | Chief Executive Officer | 100,000 0.0264% | $6.04 | $604,000 | -12.31% | |
| 2025-09-25 | Sale | Gibson Christopher | Chief Executive Officer | 100,000 0.0227% | $4.76 | $476,000 | +2.03% | |
| 2025-09-10 | Sale | Gibson Christopher | Chief Executive Officer | 100,000 0.0243% | $4.71 | $471,000 | +4.41% | |
| 2025-08-26 | Sale | Gibson Christopher | Chief Executive Officer | 100,000 0.0229% | $4.84 | $484,000 | -2.12% | |
| 2025-08-18 | Sale | Khan Najat | Chief R&D Commercial Officer | 36,599 0.0086% | $5.52 | $202,173 | -14.13% | |
| 2025-08-11 | Sale | Gibson Christopher | Chief Executive Officer | 518,175 0.121% | $5.28 | $2.74M | -9.83% | |
| 2025-03-27 | Sale | Gibson Christopher | Chief Executive Officer | 138,574 0.0355% | $6.04 | $836,987 | -18.26% | |
| 2025-03-06 | Sale | Gibson Christopher | Chief Executive Officer | 20,000 0.0051% | $6.37 | $127,400 | -20.99% | |
| 2025-03-05 | Sale | Gibson Christopher | Chief Executive Officer | 20,000 0.0051% | $6.58 | $131,600 | -25.08% | |
| 2025-02-06 | Sale | Gibson Christopher | Chief Executive Officer | 20,000 0.0053% | $8.12 | $162,400 | -30.11% |
| Borgeson Blake | director | 6649863 1.6591% | $31.45M | 0 | 62 | |
| Gibson Christopher | director | 913839 0.228% | $4.32M | 0 | 91 | |
| Taylor Ben R | Chief Financial Officer | 761550 0.19% | $3.6M | 0 | 1 | |
| Khan Najat | Chief R&D Commercial Officer | 611135 0.1525% | $2.89M | 0 | 2 | |
| Mubadala Investment Co PJSC | 10 percent owner | 12985927 3.2399% | $61.42M | 42 | 0 | <0.0001% |
| Secora Michael | Chief Financial Officer | 1499631 0.3741% | $7.09M | 0 | 34 | |
| Marriott Tina | President and COO | 521138 0.13% | $2.46M | 0 | 31 | |
| Li Dean Y | director | 421000 0.105% | $1.99M | 0 | 4 | |
| Virani Shafique | Chief Business Officer | 136748 0.0341% | $646,818.04 | 0 | 26 | |
| Lux Ventures IV, L.P. | 10 percent owner | 100000 0.0249% | $473,000.00 | 1 | 0 | <0.0001% |
| Burrell Terry-Ann | director | 54847 0.0137% | $259,426.31 | 0 | 2 | |
| Dar Zavain | director | 53823 0.0134% | $254,582.79 | 0 | 1 |
$831,902,292 | 108 | 9.34% | $1.68B | |
$100,473,344 | 83 | 9.53% | $1.87B | |
$54,590,806 | 65 | 21.84% | $2.19B | |
$1,103,317,478 | 60 | 36.54% | $1.89B | |
$47,419,530 | 58 | 17.20% | $2.22B | |
$1,376,668 | 53 | 18.46% | $1.91B | |
$1,603,489 | 30 | 98.90% | $1.72B | |
$25,045,414 | 23 | -3.79% | $1.91B | |
$75,269,735 | 23 | -2.06% | $1.74B | |
$12,094,896 | 19 | 20.07% | $1.92B | |
$154,554,190 | 14 | 29.60% | $1.66B | |
$144,557,026 | 13 | 0.49% | $1.98B | |
$94,976,497 | 10 | -10.72% | $1.68B | |
$2,859,892 | 10 | 29.21% | $1.76B | |
$25,073,947 | 7 | -5.99% | $2.12B | |
$46,235,722 | 6 | -31.77% | $1.69B | |
$7,605,533 | 5 | 17.10% | $2.17B | |
$666,380 | 5 | -16.60% | $2.03B | |
Recursion Pharmaceuticals, Inc. (RXRX) | $103,599,972 | 2 | -36.81% | $1.9B |
| Increased Positions | 168 | +47.73% | 32M | +10.43% |
| Decreased Positions | 142 | -40.34% | 18M | -6.03% |
| New Positions | 46 | New | 4M | New |
| Sold Out Positions | 55 | Sold Out | 7M | Sold Out |
| Total Postitions | 378 | +7.39% | 318M | +4.4% |
| Vanguard Group Inc | $167,077.00 | 7.74% | 39.78M | +4M | +10.28% | 2025-09-30 |
| Ark Investment Management Llc | $140,891.00 | 6.53% | 33.55M | +556,868 | +1.69% | 2025-09-30 |
| Blackrock, Inc. | $133,307.00 | 6.18% | 31.74M | +3M | +11.87% | 2025-09-30 |
| Baillie Gifford & Co | $100,711.00 | 4.67% | 23.98M | -195,120 | -0.81% | 2025-09-30 |
| State Street Corp | $76,729.00 | 3.55% | 18.27M | +7M | +63.41% | 2025-09-30 |
| Softbank Group Corp. | $61,603.00 | 2.85% | 14.67M | 0 | 0% | 2025-09-30 |
| Kinnevik Ab (Publ) | $56,424.00 | 2.61% | 13.43M | 0 | 0% | 2025-09-30 |
| Mubadala Investment Co Pjsc | $54,541.00 | 2.53% | 12.99M | 0 | 0% | 2025-09-30 |
| Mic Capital Management Uk Llp | $40,505.00 | 1.88% | 9.64M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $40,419.00 | 1.87% | 9.62M | +2M | +23.75% | 2025-09-30 |